Chengdu Aidea Pharmaceutical Technology

Chengdu Aidea Pharmaceutical Technology is a wholly-owned subsidiary of Jiangsu Aidea Pharmaceutical Group, established in 2023 as a dedicated R&D center for innovative anti-HIV therapies. Located in the Tianfu International Bio-town in Chengdu, the company focuses on the development of novel integrase inhibitors, specifically ACC017, and their combination formulations. It plays a critical role in expanding the parent company's anti-viral pipeline, which already includes the approved drugs Ainuovirine and Ainuomiti. The company's research activities encompass clinical development, pharmacology, and the creation of next-generation antiretroviral regimens to address unmet needs in HIV/AIDS treatment.